Navigation Links
Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
Date:12/6/2011

ed to determine the precise role of Nplate in the development of the adverse events. Based in part on this determination, and the data submitted from clinical trials, the FDA and Amgen have concluded that the restricted elements of the REMS can be eliminated. For this reason enrollment of prescribers, patients and institutions and mandatory collection of safety data is no longer required. 

As of Dec. 7, 2011, prescribing physicians and institutions will be able to order Nplate without enrolling themselves or patients in the Nplate® NEXUS Program. The program will continue to obtain information from already enrolled patients through Jan. 5, 2012, and Nplate® NEXUS Program support assistance will continue for 28 days after approval of the modified REMS.

About Adult ITP

In patients with immune thrombocytopenia (ITP), platelets - blood elements needed to prevent bleeding - are destroyed by the patient's own immune system. Low platelet counts leave adult ITP patients open to sudden serious bleeding events. The risk for serious bleeding events increases when platelet counts drop to less than 30,000 platelets per microliter; normal counts range from 150,000 to 400,000 platelets per microliter. ITP has historically been considered a disease of platelet destruction although recent data suggest that the body's natural platelet production processes in ITP are also unable to compensate for low levels of platelets in the blood. Increasing the rate of platelet production may address low platelet levels associated with ITP. Currently, there are approximately 90,000 adult chronic ITP patients in Europe and the U.S. ITP affects about twice as many adult women as men.

The Nplate FIRST STEP™ Co-Pay Coupon Card Program

Last year, Amgen announced its co-pay coupon umbrella program, the Amgen FIRST STEP™ Program, for commercially insured patients. As part of that program, the Nplate FIRST STEPT
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40
2. Amgen Appoints Anthony (Tony) Hooper Executive Vice President Global Commercial Operations
3. Amgen Appoints Robert A. Bradway to the Companys Board of Directors
4. Amgen Announces 2011 Fourth Quarter Dividend
5. Amgen to Present at the UBS Global Life Sciences Conference
6. Amgen Staff Volunteer Efforts Result in $5,000 For Each of Their Favorite Nonprofits
7. Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures(TM) Educational Campaign
8. Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign
9. Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research Meeting
10. Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone
11. Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... - Portage Biotech Inc. ("Portage") (OTC Market: PTGEF, ... Company Limited (Biohaven), announced today that dosing has ... a glutamate modulating agent. Biohaven filed an investigational ... clearance from the U.S. Food and Drug Administration ... 54% equity interest in Biohaven, a private company. ...
(Date:8/27/2015)... , Aug. 27, 2015 HUYA Bioscience ... meeting of the Japan Society of HTLV-1, held this ... Auditorium. The purpose of the Society is to promote ... the development of medical technology and research related to ... welfare. "HUYA is proud to support this ...
(Date:8/27/2015)... , Aug. 27, 2015 In response ... FedEx, UPS and The US Postal Service to ... classified as ,select agents, by the CDC, Marken ... handling these sensitive shipments. Marken uses ... regulations, trained and certified personnel to ensure the ...
(Date:8/26/2015)...  Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... for the detection of foodborne pathogens, today announced that ... & Company Emerging Growth Conference on September 2 at ... New York Marriott Marquis. A live ... investor relations section of Roka Bioscience,s website at ...
Breaking Biology Technology:Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Marken Ensures Safe Transportation Of Select Agents And Toxins 2
... DIEGO, Aug. 24, 2011 Biocept, Inc., a privately-held ... analysis of circulating tumor cells (CTCs) in cancer patients, ... a collaboration on the commercialization of a proprietary blood ... the determination of HER2 status.  Clarient and Biocept will ...
... PARIS and MINNEAPOLIS, Aug. 24, 2011 Cellectis ... subsidiary of Cellectis (Alternext: ALCLS), and Recombinetics, a ... entered a development and license agreement on the ... creates, in accordance with biosafety and animal well-being ...
... United Therapeutics Corporation (NASDAQ: UTHR ... Phase 3 trial of treprostinil diethanolamine (oral treprostinil), ... a stable synthetic form of prostacyclin, in patients ... that the trial did not achieve statistical significance ...
Cached Biology Technology:Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 Status in Breast Cancer Patients 2Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 Status in Breast Cancer Patients 3Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 Status in Breast Cancer Patients 4Cellectis bioresearch Grants Recombinetics an Exclusive License Agreement for the Use of Targeted Nucleases in Large Livestock 2Cellectis bioresearch Grants Recombinetics an Exclusive License Agreement for the Use of Targeted Nucleases in Large Livestock 3FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 2FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 3FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 4
(Date:8/10/2015)... , August 10, 2015 ... Eye Tracking Technology for more than two decades, announces ... for integration into all consumer display formats. The SMI ... integration of eye tracking into consumer tablets, laptops, desktop ... smart glasses. Omnivision,s leading sensor technology contributes to the ...
(Date:8/6/2015)... 2015  Today, U.S. Congressman Mike Honda ... to learn firsthand how Silicon Valley technologies can ... a world leader in multi-factor identity management and ... federal agencies and commercial organizations achieve new levels ... "The vast majority of network breaches can be ...
(Date:8/6/2015)... JOSE, Calif. , Aug. 6, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... TouchPad technologies on Windows 10. Microsoft leveraged Synaptics, ... to the operating system. Through ... drivers are fully certified with Microsoft,s Precision TouchPad ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... arrhythmia a chronic irregularity of heartbeat which ... the condition is not acutely life-threatening, it does increase ... cardiac insufficiency, stroke and dementia. In the third of ... of researchers, led by LMU physician PD Dr. Stefan ...
... SAN DIEGO - Some say the world,s population will ... will present significant challenges for agriculture to provide enough ... scientist Rod Hill., Hill and Larry Branen, a University ... American Association for the Advancement of Science annual meeting ...
... hunger could be large over the next 20 years, according ... temperatures could significantly reduce yields of wheat, rice and maize ... who subsist on less than $1 a day. The resulting ... drive many into poverty. But even as some people ...
Cached Biology News:When the heart gets out of step 2When the heart gets out of step 3Biotech, nanotech and synthetic biology roles in future food supply explored 2Global warming may hurt some poor populations, benefit others 2Global warming may hurt some poor populations, benefit others 3Global warming may hurt some poor populations, benefit others 4
E2F2 protein...
Anti-DDDDK-Tag (Enterokinase Cleavage Site), Agarose Conjugate Research Focus: tag Storage: 4C Shipping Temperature: 4C...
Goat polyclonal to XAGE1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGFGFRRQGEDNT, corresponding to C terminal amino acids 149-160 of Human XAGE1 Entrez Gene ID: 9...
Sheep polyclonal to Staphylococcus DNase ( Abpromise for all tested applications). Antigen: Full length native protein (purified)....
Biology Products: